FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by Sandoz in US
July 01, 2024 01:00 ET
|
Sandoz Group
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by Sandoz in US Pyzchiva® (ustekinumab-ttwe)...
Idorsia’s JERAYGO (aprocitentan) approved in Europe as first and only ERA for the treatment of resistant hypertension
July 01, 2024 01:00 ET
|
Idorsia Pharmaceuticals Ltd
Idorsia receives approval from the European Commission (EC) for JERAYGO™ (aprocitentan) as the first and only endothelin receptor antagonist (ERA) for the treatment of resistant hypertension.JERAYGO...
Addex Shareholders Approve All Resolutions at Annual General Meeting
July 01, 2024 01:00 ET
|
Addex Therapeutics
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 1, 2024 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric...
WISeKey Shareholders Approved All Agenda Items of the 2024 Annual General Meeting
June 28, 2024 12:26 ET
|
Wisekey International Holding Ltd.
WISeKey Shareholders Approved All Agenda Items of the 2024 Annual General Meeting Zug, Switzerland, June 28, 2024 – WISeKey International Holding Ltd. (“WISeKey” or the “Company”) (SIX: WIHN, NASDAQ:...
Higher cantonal composition authority issues written court decision in respect to the amendments to the terms of the 2024 convertible bonds
June 28, 2024 11:45 ET
|
Idorsia Pharmaceuticals Ltd
Allschwil, Switzerland – June 28, 2024 Idorsia Ltd (SIX: IDIA) today announced that it has received the written decision from the higher cantonal composition authority (obere kantonale...
Roche’s Vabysmo gets CHMP recommendation for third indication retinal vein occlusion (RVO)
June 28, 2024 07:15 ET
|
F. Hoffmann-La Roche Ltd
Positive recommendation is based on two Phase III studies. In addition to robust retinal drying with Vabysmo, these data show early and sustained vision improvements, which are non-inferior to...
CHMP recommends EU approval of Roche’s PiaSky for people with PNH, a rare, life-threatening blood condition
June 28, 2024 07:00 ET
|
F. Hoffmann-La Roche Ltd
If approved, PiaSky will be the first monthly subcutaneous (SC) treatment for paroxysmal nocturnal haemoglobinuria (PNH) in the EU Additionally, with the option to self-administer, PiaSky may provide...
Kuntarahoitus laskee liikkeeseen 250 miljoonan Englannin punnan viitelainan osana joukkovelkakirjalainaohjelmaa
June 28, 2024 03:00 ET
|
Kuntarahoitus Oyj
Kuntarahoitus OyjPörssitiedote28.6.2024 klo 10.00 Kuntarahoitus laskee liikkeeseen 250 miljoonan Englannin punnan viitelainan osana joukkovelkakirjalainaohjelmaa Kuntarahoitus Oyj laskee...
Municipality Finance issues a GBP 250 million benchmark under its MTN programme
June 28, 2024 03:00 ET
|
Municipality Finance Plc
Municipality Finance PlcStock exchange release 28 June 2024 at 10:00 am (EEST) Municipality Finance issues a GBP 250 million benchmark under its MTN programme Municipality Finance Plc issues...
Roche expands access to cervical cancer screening tools with two new WHO prequalification designations, including HPV self-collection
June 27, 2024 01:00 ET
|
F. Hoffmann-La Roche Ltd
The World Health Organization (WHO) has awarded Roche's human papillomavirus (HPV) test prequalification designations for use on the cobas 5800 System and for self-collected samples on the cobas 5800,...